All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.
| Molecular Weight | 371.48 |
| CAS Number | 245520-69-8 |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PAR Products |
|---|
| ML161
Parmodulin 2 (ML161) is an allosteric inhibitor of PAR1 with IC50 of 0.26 μM. |
| Vorapaxar
Vorapaxar (SCH 530348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM. |
| Vorapaxar Sulfate
Vorapaxar is a first-in-class, potent and orally-active protease-activated receptor 1 (PAR-1) antagonist that blocks thrombin-mediated platelet activation without interfering with thrombin-mediated fibrin deposition. |
| ML354
ML354 is a potent and selective PAR4 (protease activated receptor-4) antagonist. |
| PAR-4 (1-6) (human)
PAR-4 (1-6) (human) is an N-terminal fragment of protease-activated receptor 4 (PAR4) that acts as a PAR4 agonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
